We have previously demonstrated that the transition of melanoma to the metastatic phenotype is associated with a loss of expression of the transcription factor AP-2. To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous SB-2 melanoma cells by using a dominant-negative AP-2, or AP-2B, gene. AP-2B is an alternatively spliced AP-2 variant capable of inhibiting AP-2 trans-activator function. Stable transfection of primary cutaneous melanoma SB-2 cells with the dominant-negative AP-2B gene was con®rmed by RT ± PCR and Northern blot analyses. Electromobility shift assay using nuclear extracts from these cell lines demonstrated decreased functional binding of AP-2B-transfected cells to the AP-2 consensus binding sequence compared with neo-transfected controls. In addition, CAT activity driven by a construct containing the AP-2 consensus binding sequence was downregulated in the AP-2B transfected cells, indicating AP-2 activity was quenched in the transfected cells. Orthotopic (subcutaneous) injection of the dominant-negative (AP-2B)-transfected cell lines into nude mice increased their tumorigenicity compared to control neo-transfected cells. The AP-2B-transfected cells displayed an increase in MMP-2 expression (by Northern blot) and MMP-2 activity (by zymography), which resulted in an increase in invasiveness through Matrigel-coated ®lters. The AP-2B-transfected tumors also displayed an increase in MMP-2 expression, microvessel density, and angiogenesis in vivo. These results demonstrate that inactivation of AP-2 contributes to the progression of melanoma, at least partially via deregulation of the MMP-2 gene.
Introduction
Despite the increasing worldwide incidence of melanoma, our understanding of the molecular events of melanoma cell growth and progression remains limited. In particular, although signi®cant progress has been made in delineating the molecular changes associated with the transition of melanoma cells to the metastatic phenotype, they are not yet suciently de®ned.
Transcription factors, capable of coordinating gene expression through transcriptional activation or repression of a multitude of genes, have been implicated in the pathogenesis of malignancy and likely play a major role in the development and progression of tumors by their loss or gain of function. Recent evidence supports the belief that a variety of transcription factors are important in the pathogenesis of melanoma, including activating transcription factor-1 (ATF-1) (Bohm et al., 1995; , cAMP response elementbinding protein (CREB) Jean et al., 1998b; Rutberg et al., 1994; Xie et al., 1997b) , transcription factor AP-2 (Huang et al., 1998; Jean et al., 1998a) , micropthalmia transcription factor (Mitf) (Goding, 2000; King et al., 1999; Fang and Setaluri, 1999) , and nuclear factor-kappa B (NF-kB) . In particular, we have previously demonstrated that the transition of melanoma to the metastatic phenotype is associated with a loss of expression of the transcription factor AP-2 (Bar- Eli, 1997 Eli, , 1999 ). This concept is further supported by the recent observation that AP-2 expression inversely correlates with melanoma progression in human primary melanoma specimens (Karjalainen et al., 1998) .
The transcription factor AP-2 is a retinoic acidinducible 52 kDa protein ®rst puri®ed from HeLa cells (Williams et al., 1988) and subsequently mapped to a region on the short arm of chromosome 6 near the HLA locus (Gaynor et al., 1991; Mitchell et al., 1991) . The AP-2 protein binds to a consensus palindromic core recognition element with the sequence 5'-GCCNNNGGC-3' (Bauer et al., 1994; Williams et al., 1988) . DNA binding and dimerization are mediated by a basically charged domain preceding a helix ± span ± helix motif located in the C-terminus (Williams and Tjian, 1991a, b) . Functional AP-2 binding sites have been identi®ed in the enhancer regions of viral genes such as simian virus 40 (SV40) (Mitchell et al., 1987) , human T-cell leukemia virus type I (Nyborg and Dynan, 1990) , and cellular genes including melanoma cellular adhesion molecule (MCAM/MUC18) (Jean et al., 1998a) , tyrosine kinase receptor c-KIT (Huang et al., 1998) , thrombin receptor (Schmidt et al., 1996) , p21/WAF1 (Ropponen et al., 1999; Zeng et al., 1997) , c-myc (Gaubatz et al., 1995) , type IV collagenase/ gelatinase (Huhtala et al., 1990) , intercellular adhesion molecule (ICAM-1) (Grether-Beck et al., 1996) , inositol 1,4,5-triphosphate receptor (IP 3 R) (Williams and Tjian, 1991b) , murine major histocompatibility complex (H-2K b ) (Kanno et al., 1989) , human metallothionein-IIa (huMTIIa) (Haslinger and Karin, 1985; Lee et al., 1987) , human proenkephalin (Hyman et al., 1989) , human keratin K14 (Leask et al., 1991) , keratin 10 ( Maytin et al., 1999) , c-erb-2 (Bosher et al., 1995) , plasminogen activator inhibitor type I (PAI-1) (Descheemaeker et al., 1992) , and insulin-like growth factor binding protein-5 (Duan and Clemmons, 1995) .
AP-2 activity is regulated through a number of signal transduction pathways. Phorbol esters and signals that enhance cAMP levels induce AP-2 activity independently of protein synthesis, whereas retinoic acid treatment of teratocarcinoma cell lines results in a transient induction of AP-2 mRNA levels at a transcriptional level (Buettner et al., 1993; Imagawa et al., 1987; Luscher et al., 1989) .
AP-2 is involved in mediating programmed gene expression both during embryonic morphogenesis and adult cell dierentiation. Using in situ hybridization, a restricted spatial and temporal expression pattern has been observed during murine embryogenesis. In particular, regulated AP-2 expression was observed in neural crest-derived cell lineages (from which melanocytes are derived) and in facial and limb bud mesenchyme (Mitchell et al., 1991) . Two recent reports of AP-2-null mutant mice have demonstrated that AP-2 is important for development of the cranial region and for midline fusions. The AP-2-null mice died at birth (Luscher et al., 1989; Schorle et al., 1996; Zhang et al., 1996) .
To provide direct evidence that AP-2 plays a role in metastasis of human melanoma, we stably transfected the AP-2 gene into highly metastatic, AP-2-negative, A375SM human melanoma cells and subsequently analysed their tumorigenic and metastatic potential in nude mice. Expression of AP-2 in A375SM cells suppressed their tumorigenicity and metastatic potential in nude mice. Downregulation of the melanoma cellular adhesion molecule MCAM/MUC18 (whose expression is associated with melanoma progression) (Lehmann et al., 1989; Shih et al., 1994; Xie et al., 1997a) and upregulation of the tyrosine kinase receptor c-KIT (whose expression decreases with melanoma progression) (Huang et al., 1996; Lassam and Bickford, 1992; Zakut et al., 1993) , both of which contain multiple AP-2 binding sites in their promoter, were also observed (Huang et al., 1996 (Huang et al., , 1998 Jean et al., 1998a; Luca et al., 1993 ).
An alternatively spliced AP-2 protein, AP-2B, that diers in its C-terminus and acts as dominant-negative to AP-2, has been recently cloned (Buettner et al., 1993) . This protein contains the activation domain and part of the DNA-binding domain, but lacks the dimerization domain, which is necessary for DNA binding. Both transient and stable transfection experiments show that AP-2B inhibits AP-2 trans-activator function. Furthermore, constitutive AP-2B expression in the human teratocarcinoma cell line PA-1 causes a retinoic acidresistant phenotype, anchorage-independent growth in soft agar, and tumorigenicity in nude mice (Buettner et al., 1993) . AP-2B has also been detected by RT ± PCR in HeLa cells and the human prostate carcinoma cell line LnCAP (Buettner et al., 1993) .
The successful growth of primary melanoma tumors and development of metastases is dependent upon successful completion of a multi-step process, initial events of which include invasion and proteolytic degradation of extracellular matrix as well as neovascularization (Fidler, 1990) . Matrix metalloproteinases (MMPs) are a family of highly homologous proteolytic enzymes involved in degradation of basement membrane. (Liotta, 1980 (Liotta, , 1986 . Expression of the 72 Da type IV collagenase, also known as MMP-2 or gelatinase A, has been shown to correlate with metastatic potential in melanoma (Frisch and Morisaki, 1990; Hofmann et al., 1999; Vaisanen et al., 1998 Vaisanen et al., , 1999 Interestingly, the MMP-2 promoter has been cloned and sequenced, and contains at least one AP-2 binding element (Frisch and Morisaki, 1990; Qin et al., 1999; Somasundaram et al., 1996) .
To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous melanoma by transfecting the dominant-negative AP-2, or AP-2B, gene, based on our hypothesis that MMP-2 expression is regulated at the transcriptional level and that AP-2 speci®cally regulates MMP-2 expression in melanoma cells. In this study, we show that enforced expression of the dominant-negative transcription factor AP-2B in the poorly tumorigenic and nonmetastatic SB-2 human melanoma cell line (which constitutively expresses AP-2) resulted in: (1) decreased functional AP-2 binding; (2) increased tumor growth in nude mice; (3) upregulation of matrix metalloproteinase-2 (MMP-2) expression and activity, which also resulted in an increase in invasiveness; and (4) increased microvessel density (angiogenesis) in experimental tumors. These results provide evidence that inactivation of AP-2 expression contributes to the malignant phenotype in melanoma.
Results

Ectopic expression of dominant-negative AP-2B in SB-2 human melanoma cells
To investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in SB-2 primary cutaneous melanoma cells by using the dominant-negative AP-2, or AP-2B gene. The AP-2B transcription factor is an alternatively spliced AP-2 variant capable of inhibiting AP-2 trans-activator function (Buettner et al., 1993) . SB-2 cells are poorly tumorigenic and nonmetastatic in nude mice (Luca et al., 1997; Singh et al., 1995) and produce endogenous AP-2 (Bar-Eli, 1997). Following gene transfection with an expression vector carrying a full-length human AP-2B cDNA or an empty vector, neo-resistant colonies were pooled and established in culture. Two transfectants were obtained and designated SB2-AP-2B.3B and SB2-AP-2B.5B, respectively. Northern blot analysis using a sequence unique to AP-2B as a cDNA probe demonstrated high levels of AP-2B mRNA transcripts in the two transfectants (Figure 1a ), but not in parental SB-2 or control neo-transfected cells. Overexpression of AP-2B in the AP-2B.5B clone, which was selected for further in vitro and in vivo analysis, was also detected by RT ± PCR (Figure 1b) . Low-level expression of endogenous AP-2B was found in a variety of melanoma cell lines; no correlation with their known in vivo experimental metastatic potential was observed (data not shown).
To determine whether AP-2B-transfected cells had decreased functional AP-2 binding, we next analysed the ability of proteins in nuclear extracts from the transfected cells to bind to a consensus AP-2-binding DNA oligonucleotide on an EMSA gel. Parental SB-2 cells (which constitutively express transcription factor AP-2) served as a positive control. As shown in Figure 2a To further demonstrate that the constitutive AP-2 in the AP-2B-transfected cells was less transcriptionally active, we took advantage of the observation that AP-2 trans-activates the metallothionein promoter by binding to its AP-2-binding site (Bauer et al., 1994) . We constructed a CAT reporter gene expression vector driven by a trimer of AP-2 consensus response elements from the human metallothionein gene IIA ligated in front of a minimal TK promoter (Huang et al., 1998) . The reporter constructs were transfected into control or AP-2B-transfected SB-2 cells. The pB-actin-RL plasmid was also transfected and served as an internal control for transfection eciency. CAT activity was signi®cantly decreased (by 25-fold) in the AP-2B transfectant AP-2B.5B (lane 5) compared with SB-2 parental (lane 3) or neo-control cells (lane 4) (Figure 2b ). These data demonstrate that AP-2B-transfected SB-2 cells produced high levels of active AP-2B, which in turn decreased the functional binding of endogenous AP-2 in these cells and decreased AP-2 transcriptional activity. We previously demonstrated that enforced AP-2 expression in the highly metastatic A375SM human melanoma cells decreases tumor growth and metastatic potential in nude mice (Huang et al., 1998; Jean et al., 1998a) . To determine the tumorigenicity of the AP-2B-transfected SB-2 cells, which exhibited decreased functional AP-2 activity, we injected 1610 6 cells s.c. into BALB/c nude mice and monitored tumor growth weekly. We chose the AP-2B.5B clone, which expressed higher levels of the dominant-negative AP-2B transcript ( Figure 1b ). Neo-transfected control cells produced tumors of only 0.3 cm in mean diameter by 6 weeks (Figure 3 ). In contrast, the AP-2B-transfected SB-2 cells produced tumors with a mean diameter of 1.2 cm, indicating that transfection of AP-2B into SB-2 cells enhanced tumor growth in vivo. The increase in tumor growth in the SB-2-AP-2.5B cells was not due to dierences in cell division time, as no signi®cant dierences in cell doubling time were found between the SB-2 neo-transfected and AP-2B-transfected cell populations cultured in vitro in the presence of dierent concentrations (0.5, 1, 5 and 10%) of fetal bovine serum (data not shown).
In the next set of experiments we analysed the metastatic potential of the AP-2B-transfected cells using the experimental lung metastasis assay. We found that while the control neo-transfected cells did not metastasize to the lungs in any of the mice (0/10), lung metastases were found in three out of 10 mice injected with the AP-2B transfected cells. In each one of these mice, 2 ± 5 lung colonies were observed and their melanoma origin was con®rmed by H & E staining and histologic examination.
Regulation of MMP-2 mRNA expression
The ability of tumor cells to grow depends on proper vascularization of the tumor and its ability to degrade type IV collagen. Activation of the type IV collagenase (MMP-2) may account for the increased tumorigenicity of the AP-2B-transfected cells. The alteration of the extracellular matrix (ECM) by MMP-2 allows endothelial cells to migrate through the ECM towards the tumor and enhance neovascularization. Since the MMP-2 promoter contains an AP-2 binding site (Frisch and Morisaki, 1990; Qin et al., 1999; Somasundaram et al., 1996) , and since transfection of SB-2 cells with AP-2B was associated with increased tumorigenicity in nude mice, we next evaluated the eect of AP-2B on MMP-2 expression. Expression of MMP-2 in the AP-2B transfected cells was analysed by Northern blot analysis (Figure 4a To con®rm that AP-2B upregulates MMP-2, we constructed a luciferase reporter gene expression vector driven by the MMP-2 promoter (7390 to +290) linked upstream of luciferase, which contains an AP-2 consensus binding sequence (Huhtala et al., 1990) . As shown in Figure 4b , luciferase activity driven by the MMP-2 promoter was signi®cantly upregulated (by threefold) in the dominant-negative AP-2B stably transfected cells, but not in parental or neo-transfected cell lines, suggesting that AP-2 is involved in MMP-2 transcription. In addition, SB-2 cells stably transfected with wild-type AP-2 (SB-2.AP-2 w.t.), which overexpress AP-2, had virtually no detectable luciferase activity.
The promoter analysis ( Figure 4b ) indicated that AP-2 is an important regulator of MMP-2 gene expression. To further assess the eect of AP-2 on MMP-2 transcription, an MMP-2 promoter-CAT construct was co-transfected into highly metastatic A375SM cells (AP-2-negative) with increasing concentrations of an expression vector encoding wild-type AP-2 (pSG5-AP-2) or with a control vector lacking the AP-2 cDNA (pSG5). Figure 4c demonstrates that CAT activity driven by the MMP-2 promoter was inhibited by AP-2 in A375SM cells in a dose-dependent manner (lanes 5 ± 10). Collectively, these experiments indicate that functional AP-2 elements occur within the MMP-2 promoter that regulate MMP-2 expression in human melanoma cells and that, while wild-type AP-2 downregulates MMP-2 transcription, AP-2B expression enhances MMP-2 transcription and expression. We conclude that AP-2B's ability to enhance MMP-2 expression and activity may explain the observed increase in tumorigenicity.
Increased MMP-2 activity in AP-2B-transfected SB-2 cells
Since AP-2B overexpression was associated with increased MMP-2 expression, and since MMP-2 is a 
Melanoma cell migration through matrigel-coated filters
We next examined whether the increase in MMP-2 activity in the AP-2B-transfected cells is re¯ected in their ability to penetrate through the basement membrane, an important component in the process of tumor growth and metastasis. SB-2 parental and neotransfected cells had a low potential to penetrate the Matrigel-coated ®lters ( Figure 6 ). In contrast, AP-2B-transfected cells exhibited increased invasiveness Note that a similar cell line stably transfected with wild-type AP-2 had virtually no detectable luciferase activity (Activity relative to Neo=100). (c) Eect of wild-type AP-2 on MMP-2 transcription in A375SM cells. The MMP-2-CAT construct was transfected into highly metastatic A375SM along with increasing concentrations of AP-2 expression vector. CAT activity driven by the MMP-2 promoter was downregulated by increasing concentrations of AP-2 in a dose-dependent manner. Lane 1, cells transfected with the SV40 positive control vector. Lane 2 ± 4, control cells transfected with decreasing concentrations of AP-2 and control vector (without MMP-2). Lanes 5 ± 10, cells transfected with MMP-2-CAT with decreasing concentrations (7 ± 0 mg) of AP-2 expression vector Figure 6 Eect of AP-2B expression on migration through Matrigel-coated ®lters. SB-2 cells before and after transfection with the dominant-negative AP-2B gene were assayed for their potential to penetrate ®lters coated with Matrigel. Parental (PC) and neo-transfected SB-2 cells were less able to penetrate through Matrigel-coated ®lters than AP-2B transfected cells, which exhibited an increased ability to invade through these ®lters. (PC-=unconditioned medium) through these ®lters. These studies revealed that expression of AP-2B by melanoma cells increases their capacity to penetrate the basement membrane, and they suggest a speci®c role for AP-2B in the migration and invasion of melanoma cells.
Increased expression of MMP-2 in AP-2B-transfected tumors in situ
Since increased MMP-2 activity was observed in AP-2B-transfected cells in vitro, we next examined whether the same phenomenon was observed in tumors derived from AP-2B-transfected SB-2 melanoma cells in their natural microenviroment. Increased MMP-2 expression was observed by in situ hybridization in the AP-2B-transfected tumors (Figure 7e ) compared to neotransfected controls (Figure 7f ) (P50.05). Figure 7 depicts representative sections of more than six specimens examined.
Anti-CD31 staining and microvessel density in experimental tumors
Type IV collagenase/gelatinase/MMP-2 is involved in a wide array of biological activities, including invasion and angiogenesis. Since the AP-2B-transfected cells displayed increased MMP-2 activity, we sought to determine whether the increase in their tumorigenicity and metastatic potential in vivo was associated with an increase in mean microvessel density within experimental tumors. To this end, we injected SB2-AP-2B.5B or SB-2-neo cells subcutaneously into nude mice. 
Discussion
In this paper we provide further evidence that the transcription factor AP-2 plays a pivotal role in regulating tumor growth of human melanoma by inactivating AP-2 in primary cutaneous melanoma using the dominant-negative AP-2B gene. AP-2B transfection downregulated w.t. AP-2 transcriptional activity and increased tumorigenicity in nude mice. This could be partially explained by the increase in MMP-2 expression and activity, which resulted in an increase in invasiveness through Matrigel-coated ®lters, and microvessel density (angiogenesis) in vivo.
Recent studies from our laboratory suggest that loss of AP-2 may be critical for the development and progression of human melanoma (Bar-Eli, 1997 Huang et al., 1998; Jean et al., 1998a) . In these studies, re-expression of AP-2 in highly metastatic A375SM cells resulted in decreased tumorigenicity and in inhibition of metastatic potential in nude mice (Huang et al., 1998; Jean et al., 1998a) . MCAM/MUC18 mRNA and protein expression was signi®cantly downregulated, while c-KIT expression was upregulated in the AP-2-transfected cells. In our proposed model, AP-2 plays a pivotal role in regulating the expression of several genes whose protein products are involved in tumor growth and metastasis of melanoma. Some of the potential functional changes by which loss of AP-2 expression in melanoma contributes to the metastatic phenotype may be explained by alterations in function of one or more of several genes whose promoters contain at least one AP-2-binding sequence. As such, AP-2 may regulate genes that are important in acquisition of the metastatic phenotype, including genes involved in proliferation (p21/WAF-1, HER-2, c-KIT, bcl-2); adhesion (MCAM/MUC18, E-cadherin); and invasion/angiogenesis (MMP-2, plasminogen activator inhibitor type-1, MCAM/MUC18) (Bar-Eli, 1999) .
In the process of angiogenesis, endothelial cells must breech the ECM and extend toward the source of the angiogenic stimulus (Liotta et al., 1980; Liotta and Stetler-Stevenson, 1990 ). Proteolysis of the ECM by MMP-2 permits endothelial cell migration and may also release sequestered angiogenic molecules such as vascular endothelial growth factor and basic ®broblast growth factor. MMPs are implicated in this process by their expression in and around forming blood vessels (Blood and Zetter, 1990) and by their ability to modulate endothelial cell proliferation and microtubule formation in vitro (Karelina et al., 1995) . Moreover, MMP-2 activity has been shown to correlate with metastatic potential in melanoma (Frisch and Morisaki, 1990; Hofmann et al., 1999; Vaisanen et al., 1998 Vaisanen et al., , 1999 , and its promoter contains at least one AP- (Frisch and Morisaki, 1990; Qin et al., 1999; Somasundaram et al., 1996) . We demonstrate here that AP-2B-transfected cells displayed increased MMP-2 mRNA expression and function (type IV collagenase activity and invasion via Matrigel) and increased microvessel density. Luciferase activity driven by the MMP-2 promoter was upregulated in the dominant-negative AP-2B stably transfected cells (Figure 4b ), but not in parental or Neo-transfected cell lines, supporting that the AP-2B is functional. The role of AP-2 was also supported by data gathered using an alternate approach (Figure 4c ), whereby increasing amounts of AP-2 (wild-type) transfected into highly metastatic A375SM (which express minute levels of AP-2) resulted in decreased CAT activity driven by the MMP-2 promoter. Moreover, we observed increased MMP-2 expression by AP-2B in the AP-2B tumors in vivo (Figure 7) . This approach was utilized since MMP-2 is a secreted protein and immunohistochemistry would therefore be less informative. Expression of AP-2B in SB-2 cells rendered these cells metastatic in nude mice, although a low incidence of metastases was observed. While other molecular changes are probably needed for the acquisition of a fully aggressive metastatic potential, these results demonstrate that inactivation of AP-2 contributes to the progression of melanoma, at least partially via deregulation of the MMP-2 gene. This paradigm is consistent with the notion that multiple molecular events are required for the development of metastatic melanoma. Indeed, other molecular events, such as loss of C-KIT and overexpression of MUC18/MCAM, IL-8 and ATF1/CREB, are likely needed to acquire the aggressive metastatic phenotype (Bar-Eli 1997 .
The mechanism by which melanoma cells displaying a metastatic phenotype are associated with decreased AP-2 expression remains unclear and is currently under investigation. One possible explanation is to link the lack of AP-2 expression to cytogenetic evidence demonstrating deletions of the distal portion of the long arm of chromosome 6 (Pathak et al., 1983; Trent et al., 1989) , or importantly, abnormalities in the short arm of chromosome 6 near the HLA locus (in proximity to the AP-2 gene) (Gaynor et al., 1991; Real et al., 1998) . Indeed, both deletions and loss of heterozygosity have been reported in this region in melanoma (Copeman, 1992; Healy et al., 1995; Zhang et al., 1995) . Since reintroduction of chromosome 6 into metastatic melanoma cells inhibited their tumorigenicity and metastatic potential (Trent et al., 1989; Welch et al., 1994) , inactivation of a tumor suppressor gene on chromosome 6 may be a critical event in the progression of melanoma. In one recent study (Karjalainen et al., 2000) , immunohistochemistry and in situ hybridization were performed on 52 primary melanomas to evaluate AP-2 mRNA and protein expression. While mRNA and protein expression were concordantly positive or negative in 36/52 (69%) specimens, 16 of 25 (64%) specimens expressed mRNA in AP-2 protein-negative areas, suggesting that at least in some cases, AP-2 may be inactivated as a result of failure of post-transcriptional processing.
While the above explanation is possible, other mechanisms may also contribute to the loss of AP-2 expression observed with melanoma progression. Indeed, a recent study suggests that a positive coactivator, PC4, may be a limiting cofactor of AP-2-mediated transcriptional activation (Kannan et al., 1999) . Alternatively, UV radiation, which plays a major role in the development of at least some cutaneous melanomas (Holman et al., 1980) , (Romerdahl et al., 1988) , has recently been shown to be capable of altering AP-2 activity in human keratinocytes and the epidermoid carcinoma cell line A431 (Ariizumi et al., 1996; Grether-Beck et al., 1996) . Whether coactivator PC4 or UV radiation can aect AP-2 expression and AP-2 activity in human primary cutaneous melanoma is currently unknown.
In summary, our results demonstrate that inactivation of the transcription factor AP-2 using stable transfection with the dominant-negative AP-2B gene in human melanoma cells constitutively expressing AP-2 decreased functional AP-2 activity and increased tumor growth and angiogenesis in vivo. Moreover, AP-2B-transfected cells demonstated increased MMP-2 mRNA expression and activity, which is likely regulated at the transcriptional level. These data demonstrate that AP-2 may be useful not only as a new molecular staging marker, but as a common target for anti-tumor and anti-metastasis therapy.
Materials and methods
Cell lines and culture conditions
The A375-P human melanoma cell line was established in culture from a lymph node metastasis of a melanoma patient (Li et al., 1989) . The highly metastatic derivative A375SM line was established from pooled lung metastases produced by the A375-P cells injected i.v. into nude mice (Li et al., 1989) . The SB-2 cell line was isolated from a primary cutaneous lesion (Verschraegen et al., 1991) and was a gift of Dr B Giovanella (St. Joseph's Hospital Cancer Center, Research Laboratory, Houston, TX, USA). In nude mice, SB-2 cells are poorly tumorigenic and nonmetastatic (Luca et al., 1993; Singh et al., 1995; Xie et al., 1997a) . Mel888 cells are low tumorigenic and nonmetastatic in nude mice (kindly provided to us by Dr Ruth Halaban, Yale University, New Haven, CT, USA), while the WM2664 cells are tumorigenic and metastatic in nude mice (kindly provided to us by Dr Meenhard Herlyn, Wistar Institute, Philadelphia, PA, USA). The melanoma cell lines were maintained in culture as adherent monolayers in Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, nonessential amino acids, L-glutamine, and penicillin-streptomycin (Flow Laboratories, Rockville, MD, USA), and buered with 10 mM HEPES (Life Technologies, Inc., Rockville, MD, USA), and incubated in 5% CO 2 , 95% air at 378C. Cultures were maintained for no longer than 4 weeks after recovery from frozen stocks. The stably transfected SB-2 cell lines were maintained in the same medium containing 0.5 mg/ml G418 (Life Technologies, Inc., Rockville, MD, USA).
Stable transfection of melanoma cells with AP-2B
SB-2 cells were transfected using 15 ml of lipofectin reagent according to the manufacturer's instructions (Life Technologies, Inc., Rockville, MD, USA) with pSG5-neo-AP-2B expression vector containing the full-length cDNA or control pSG5-neo vector as described previously (Buettner et al., 1993) . At 10 h following transfection, the medium was changed to serum-containing complete medium, and the cells were incubated for an additional 48 h at 378C. Cells were selected after 48 h with standard medium containing G418 (0.5 mg/ml). Fourteen days later, neo-resistant colonies were harvested by trypsinization, pooled, and established in culture.
RT ± PCR
Melanoma cells (5610 5 ) were seeded onto 100-mm Petri dishes in culture medium and grown to 80% cell con¯uence. The cells were washed with PBS, then lysed in 1 ml Trizol (Life Technologies, Inc.). Total RNA was puri®ed according to the manufacturer's instructions and quanti®ed by UV absorbance at 260 nm. Total RNA (1 mg) was reverse-transcribed with 200 units MMLV reverse transcriptase, using 20 pmole of oligo (dT) 18 primer (Clontech Lab, Inc.). The resultant cDNA was diluted 1 : 4 with DEPC-treated dH 2 O. PCR was performed on a 10 ml aliquot of the diluted cDNA with AP-2B cDNA sequence-speci®c primers (PNAP2B forward, 5'-GCGAATCCACTTGCTAACTAGAAGG-3' and PNAP2B reverse, 5'-ATAACCCTGAGCTTTCAGGATGGTC-3') (Buettner et al., 1993) , and a GAPDH primer mix (Clontech Lab, Inc.) with AvanTaq Plus DNA Polymerase (Clontech Lab, Inc.), for 27 cycles (1 min at 948C, 1 min at 588C and 1 min at 728C). AP-2B cDNA-speci®c primers are expected to yield a 430 bp fragment. The RT ± PCR products were normalized by the GAPDH product, separated by electropheresis on a 1.5% SeaKem GTG agarose gel (BMA, Rockland, ME, USA) in TAE buer, and stained with ethidium bromide (Bio-Rad Lab, Hercules, CA, USA).
Northern blot analysis
mRNA was extracted from 10 6 ± 10 7 cultured cells using the FastTrack TM kit (Invitrogen Co., San Diego, CA, USA). For Northern blot analysis, 2.5 mg of puri®ed mRNA was separated on a 1% denaturing formaldehyde/agarose gel, electrotransferred at 0.6 A to GeneScreen nylon membrane (DuPont Co., Boston, MA, USA), and UV cross-linked with 120 000 mJ/cm 2 using a UV Stratalinker 1800 (Stratagene, La Jolla, CA, USA). Hybridizations were performed as previously described (Luca et al., 1995) , and ®lters were washed three times with 30 mM NaCl, 3 mM sodium citrate, pH 7.2, with sodium dodecyl sulfate (0.1% w/v) at 608C.
The DNA probes used in these analyses consisted of the PCR product for the previously described AP-2B sequencespeci®c primers with the pSG5-neo-AP-2B vector serving as a template (Kannan et al., 1994 ) and a 1.3 kb Pstl cDNA fragment corresponding to rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Fort et al., 1985) . Each DNA fragment was puri®ed by agarose gel electrophoresis, recovered using Gene Clean (BIO 101, La Jolla, CA), and radiolabeled by the random primer technique using [a-32 P]-deoxyribonucleotide triphosphates.
Preparation of nuclear extracts
Melanoma cells (5610 5 ) were seeded onto 100-mm Petri dishes in culture medium and grown to 80% cell con¯uence. The cells were washed with cold PBS, and then scraped o over ice and pelleted. The cell pellet was resuspended in 400 ml of 10 mM HEPES buer, pH 7.9, containing 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, and protease cocktail, incubated on ice for 10 min, and lysed with a Dounce tissue grinder until over 80% of the nuclei were released, as determined by Trypan blue staining. The cytoplasmic fraction was separated by centrifugation at 15 000 r.p.m. for 30 s at 48C. The nuclear pellet was resuspended in 50 ml of 20 mM HEPES buer, pH 7.9, containing 25% glycerol, 450 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, and protease cocktail, and incubated for at least 30 min on ice. The soluble nuclear proteins were separated from the insoluble material by centrifugation for 2 min at 15 000 r.p.m. The soluble nuclear protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Lab., Hercules, CA, USA).
Electrophoretic mobility shift assay (EMSA).
EMSA was performed with the following oligonucleotides as probes and/or competitors: The AP-2 oligonucleotide has the sequence 5'-GATCGAACTGACCGCCCGCGGCCCGT-3', corresponding to the human AP-2 binding site consensus sequence (Stratagene). 32 P-labeled oligonucleotide (20,000 c.p.m.) was incubated for 30 min on ice with 5 mg of nuclear extract in 20 ml binding buer containing 25 mM HEPES pH 7.5 ± 8, 0.5 mM EDTA, 0.5 mM dithiotreitol, 4% glycerol, 50 mM NaCl, and 0.5 mg of poly (dI-dc). Competition reactions were pre-incubated in binding buer for 30 min on ice with 100-fold cold oligonucleotide followed by a 30 min incubation on ice with the labeled oligonucleotide. For supershift analysis, the samples were incubated for an additional hour on ice with 1 ml anti-AP-2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The bound and free DNA were resolved by electropheresis through a 5% polyacrylamide gel at 200 V in 0.56TBE at 48C. Dried gels were exposed to Kodak Bio-Max ®lm at 7808C with intensifying screens.
Expression/Reporter vectors
The MMP-2 promoter luciferase (pMMP2-Luc) construct was generated by cutting the MMP-2 promoter region, 7390 to +290 (Huhtala et al., 1990) , out of p682-basic (CAT-driven MMP-2 promoter) (Luca et al., 1997) at the HindII/XbaI sites and ligating into pGEM-9Zf(7) vector (Promega) using the same sites. The MMP-2 promoter region was then removed via the SpeI/SalI sites and ligated into the pGL3-Enhancer (Promega, Madison, WI, USA) at the NheI/XhoI sites. The trimer-AP-2 binding site-CAT reporter construct (p36AP-2-CAT) was generated as previously described (Kannan et al, 1994; Buettner et al, 1993) . The AP-2 expression plasmids pSG5-AP-2, pSG5-neo-AP-2, and pSG5-neo-AP-2B and their control vectors pSG5 and PSG5-neo were previously described (Kannan et al., 1994) and were kindly provided to us by Dr M Tainsky (Wayne State University, USA).
Transient transfection and CAT assays
SB-2 melanoma cells (2610 5 ) were transfected by using 10 ml lipofectin reagent (Gibco Life Technologies, Rockville, MD, USA), using either 50 ng of pB-actin-RL (Huang et al., 1998) and 2 mg of one the following CAT expression vectors: the basic CAT expression vector (pCAT-basic), a positive control plasmid with SV40 promoter (pCAT-promoter) (Promega, Madison, WI, USA), or the MMP-2 promoter (p682-Basic). To further assess the eect of AP-2 on MMP-2 transcription, highly metastatic A375SM cells were transiently cotransfected with 2.5 mg of a b-galactosidase (b-gal) or Renilla luciferase expression plasmid controlled by the viral thymidine kinase promoter or the b-actin promoter, respectively (Clontech, Palo Alto, CA, USA), and 2.5 mg of the MMP-2 promoter CAT construct, along with increasing concentrations of the AP-2 wild-type expression vector pSG5-AP-2. Five to 20 h after transfection, the non-serum-containing medium (OPTI-M, Life Technologies) was replaced with supplemented MEM without G418. The cells continued to grow for 48 or 72 h at 378C. The CAT vector/Renilla luciferase plasmid or b-gal cotransiently transfected cells were washed twice with PBS and lysed in reporter lysis buer (Promega, Madison, WI, USA). After cell debris was removed by centrifugation, cell extracts were assayed for Renilla luciferase activity using the dual luciferase reporter assay system (Promega, Madison) or b-gal activity. Samples were normalized to the same relative luciferase or b-gal activity and assayed for CAT activity (Xie et al., 1997b) . The cell extracts were incubated with 0.025 mCi of [14-C]chloramphenicol and 0.35 mM acetylcoenzyme A (Sigma, St. Louis, MO, USA) in 25 mM TrisHCl, pH 7.9, for 2 h at 378C. The nonacetylated forms of chloramphenicol were extracted in ethyl acetate and separated by thin-layer chromatography on a silica gel with uorescent indicator (Kodak), using chloroform/methanol (95 : 5). Chloramphenicol acetyltransferase (CAT) activity was measured by the conversion of [14-C] chloramphenicol into acetyl-and diacetylchloramphenicol. Each assay was repeated at least three times; there was less than 10% variation between individual transfections.
Transient transfection and luciferase assay
Melanoma cells (2610 5 ) were transfected by using 10 ml lipofectin reagent (Gibco Life Technologies), using 50 ng of pB-Actin-RL and 2 mg luciferase expression vectors: the basic Luc + expression vector with no promoter/enhancer sequence (pGL3-Basic), a positive control vector with SV40 promoter and enhancer (pGL3-control) (Promega, Madison, WI, USA), or the MMP-2 promoter/SV40 enhancer (pMMP2-Luc). Five to 20 h after transfection, the medium without serum (OPTI-M, Life Technologies) was replaced with supplemented MEM without G418. After a 48 ± 72 h incubation at 378C, the co-transfected cells were washed with PBS and harvested in passive lysis buer (Promega, Madison). The ®re¯y and Renilla luciferase activities were quantitated using the dual-luciferase reporter assay system (Promega, Madison). Normalization of the transfection eciency was achieved by standardization to Renilla activity. Fold activation or inhibition of luciferase activity was calculated relative to control cells, which were given the reference value of 100 (Janknecht and Hunter, 1997) . Each assay was repeated at least three times, and there was less than 10% variation between individual transfections.
Zymography
Parental and transfected cells were plated to 20% con¯uency in six-well plates and allowed to adhere overnight in modi®ed essential medium (MEM) supplemented with 10% FBS, sodium pyruvate, essential amino acids, and penicillinstreptomycin. The cells were then washed twice in serumfree medium, and 1.5 ml of fresh serum-free medium was added to each well. After 24 h, the conditioned medium was collected, centrifuged to remove any suspended cells, and maintained at 48C. Following trypsinization, the cells in each well were quantitated using a hemacytometer. Sample volume was standardized based on adherent cell number per well and loaded onto an SDS-polyacrylamide gel (7.5%) containing gelatin (1 mg/ml) under nonreducing conditions. Following electrophoresis at 150 V, the gel was washed twice630 min in 50 mM Tris-HCl, pH 7.5, with 5 mM CaCl 2 and 1 mM ZnCl 2 containing 2.5% Triton X-100, followed by overnight incubation at 378C. The gels were then stained with Coomassie G 250 (Bio-Rad, Richmond, VA, USA) in 50 mM Tris-HCl, pH 7.5, with 5 mM CaCl 2 and 1 mM ZnCl 2 containing 1.0% Triton X-100 in methanol/acetic acid/H 2 O (40 : 10 : 50; vol/vol/vol).
Invasion assay through matrigel
Wells and Matrigel-coated inserts of a commercially available 24-well invasion chamber (Bectin-Dickinson, Bedford, MA, USA) were rehydrated in 0.5 ml of serum-free medium overnight and processed according to the manufacturer's instructions. Brie¯y, ®broblast-conditioned medium was prepared by overnight incubation of a 70 ± 80% con¯uent 162 cm 2¯a sk of NIH3T3 ®broblasts in 12 ml of serum-free medium and centrifuged (15 000 g for 5 min) to remove cells. Seven hundred and ®fty microliters of conditioned medium was added to each well as a source of chemo-attractant. Single-cell suspensions of parental and transfected cell lines were prepared at 1610 6 cells/ml, and 0.5 ml was added to each Matrigel-coated insert in triplicate. Cells and conditioned medium-containing chambers were then incubated for 22 h at 378C in 5% CO 2 ± 95% air to allow for cell invasion from the interior of each insert to the undersurface of the membrane. Residual Matrigel and nonmigrating cells were then removed. Cells invading through the invasion chamber to the opposite side of the porous membrane were then ®xed and stained, visualized, and counted using a bright-®eld microscope.
Oligonucleotide probes
A speci®c antisense oligonucleotide DNA probe for MMP-2 was designed complementary to the mRNA transcript and tested for speci®city using Northern blot analysis as previously described (Kuniyasu et al., 1999 Herbst et al, 2000) . A poly d(T) 20 oligonucleotide was used to verify the integrity of mRNA in each sample. The DNA probes were synthesized with six biotin molecules at the 3' end via direct coupling using standard phosphormidine chemistry (Research Genetics, Huntsville, AL, USA). The lyophilized probes were reconstituted to a 1 ug/ul stock solution in probe diluent (Research Genetics) and aliquoted for storage. Immediately prior to use each probe was thawed and diluted to the appropriate working dilution: 1 : 50 for MMP-2 and 1 : 600 for polydT, respectively.
In situ hybridization
ISH was performed as previously described (Kuniyasu et al., 1999 Herbst et al, 2000) using the Microprobe manual staining system (Fisher Scienti®c, Pittsburgh, PA, USA). Representative frozen sections from each mouse tumor were cut onto silane-coated ProbeOn slides (Fisher Scienti®c) and ®xed in 4% paraformaldehyde for 10 min. The slides were then placed in a Microprobe slide holder, and washed four times in 50 mM Tris buer/0.25% Brij in diethylpyrocarbo-nate treated water, pH 7.6. Hybridization with each probe was carried out at 458C for 60 min after a 4 min incubation at 1008C to denature RNA in the specimen. Specimens were then washed three times with 26SSC for 2 min at 458C (16SSC=0.15 M NaCl, 0.015 M sodium citrate). Samples were then incubated for 30 min in alkaline phosphataselabeled avidin at 458C, rinsed for 1 min with alkaline phosphatase enhancer (Biomeda Corp., Foster City, CA, USA), and incubated for 30 min with the chromagen substrate FastRed (Research Genetics) at 458C. The phosphatase enhancer rinse and chromogen incubation were repeated once. Specimens were then rinsed in water 56for 2 min and mounted using Universal Mount (Research Genetics). A positive reaction stained red. Control for endogenous alkaline phosphatase activity included treatment of the samples with chromagen alone in the absence of any biotinylated oligonucleotide probes.
All specimens were stained for both poly d(T) 20 and MMP-2 in the same run. Staining results were quanti®ed by ®rst capturing images of stained sections using a Zeiss photomicroscope (Carl Zeiss, Inc., Thornwood, NY, USA) at 1006magni®cation attached to a three-chip charge-coupled device color camera (model DXC-960 MD; Sony Corp., Tokyo, Japan) and Optimas imaging analysis software (version 6.2; Bothell, WA, USA). Staining intensity was quanti®ed as previously described (Kuniyasu et al., 1999 Herbst et al., 2000) . Brie¯y, images were prescreened to determine the range of staining intensity of the slides to be analysed and a threshold value based on these sections was set. All subsequent images were quanti®ed based on this threshold. The absorbance was quanti®ed from a representative ®eld at the periphery of each tumor. The intensity of staining was standardized to that of the integrated absorbance of poly d(T) 20 from serial sections. Statistical analysis was performed using Statistica software (version 6.0, Statsoft, Inc., Tulsa, OK, USA), and graphical data was prepared using GraphPad Prism (version 3; GraphPad Software, Inc., San Diego, CA, USA).
Animals
Male athymic nude mice (BALB/c background) were obtained from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD, USA). The mice were housed in laminar¯ow cabinets under speci®c pathogen-free conditions and used at 8 weeks of age. Animals were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Agriculture, Department of Health and Human Services, and the NIH. Their use in these experiments was approved by the Institutional Animal Care and Use Committee.
Tumor cell injections
To prepare tumor cells for inoculation, cells in exponential growth phase were harvested by brief exposure to 0.25% trypsin-0.2% EDTA solution (w/v). The¯ask was sharply tapped to dislodge the cells, and supplemented medium was added to produce a single-cell suspension. The cells were washed and resuspended in Ca 2+ -and Mg
2+
-free HBSS to the desired cell concentration. Cell viability was determined by trypan-blue exclusion, and only single-cell suspensions of more than 90% viability were used. Subcutaneous tumors were produced by injecting 1610 6 tumor cells in 0.2 ml HBSS over the right scapular region. Growth of s.c. tumors was monitored by daily examination of the mice and weekly measurement of tumors with calipers. The mice were killed 49 days after injection, and tumors were processed for hematoxylin and eosin and immunoshistochemical staining.
To produce experimental lung metastasis, 2610 6 viable tumor cells suspended in 0.2 ml of HBSS were injected into the lateral tail veins of unanesthetized mice. The mice were killed 8 week later, and the lungs were removed, washed, and ®xed in Bouin's solution to dierentiate the neoplastic lesions from the organ parenchyma. The lung nodules were counted with the aid of a dissecting microscope.
Anti-CD31/PECAM immunohistochemistry
Tumor microvasculature was evaluated immunohistochemically using tumor tissue thin sections harvested from nude mice following s.c. injection (see above). Tissue sections were frozen in Tissue-Tek O.C.T. (Sakura/Finetek, Torrance, CA, USA). Five-micrometer sections were prepared and ®xed sequentially in acetone, acetone:chloroform (1 : 1; vol/vol), and acetone alone; and rinsed in PBS. Endogenous peroxidase was blocked by treatment with 3% H 2 O 2 in methanol. The sections were again washed in PBS and incubated for 20 min with a nonspeci®c blocking solution consisting of PBS containing 5% normal horse serum and 1% normal goat serum. The sections were then incubated with rat anti-mouse CD31/PECAM monoclonal primary antibody (Pharmingen International, San Diego, CA, USA) diluted (1 : 300) in blocking solution and incubated in a humidi®ed chamber at 48C for 18 h, washed in PBS, and incubated with second antibody (horseradish peroxidaseconjugated goat anti-rat immunoglobulin G; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; 1 : 200 dilution) for 1 h at 228C. AEC chromogen (AEC Substrate Pack, Biogenex, San Ramon, CA, USA) was prepared and utilized according to manufacturer's instructions. Progress of the colorimetric reaction was monitored under a bright®eld microscope. Prior to counterstaining, sections were mounted using Universal Mount (Research Genetics, Huntsville, AL, USA) according to supplier's instructions, and image analysis was performed (see below). The aqueous mounting medium was then dissolved for 45 min in distilled water, and sections were counterstained with Gill's hematoxylin for 10 ± 20 s and remounted for longterm preservation. Negative controls were exposed to identical conditions except that blocking solution alone was used in place of the primary antibody.
Staining patterns were quanti®ed by the capture of at least ®ve images of areas of high vessel density (hot spots) per tumor section using a Zeiss photomicroscope (Carl Zeiss, Inc., Thornwood, NY, USA) at 1006magni®cation attached to a three-chip charge-coupled device color camera (model DXC-960 MD; Sony Corp., Tokyo, Japan). Image analysis software (Optimas version 6.2; Bothell, WA and Scion Image Beta version 4.02 for Windows, Scion Corporation, Frederick, MD, USA) was then used to quantify microvessel density.
